Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
SR Pharma reports data on toxicology studies for systemically delivered RNAi cancer compound
February 27th, 2007
SR Pharma plc (SPA) announced the successful completion of further toxicology studies for its RNAi product candidate Atu027, which is being developed for systemic cancer indications. The studies were conducted by an independent clinical research organization and the results allow SR Pharma to proceed with a full toxicological evaluation of Atu027 in 28-day toxicity studies prior to commencing clinical testing later this year. The latest preclinical toxicology data were presented at an industry meeting, "RNAi for Target Validation and as a Therapeutic," in Keystone, Colorado, U.S. Atu027 is designed to inhibit the function of a...
Source: Cancer Weekly (2007-02-27)
|
